Vol 31, No 6 (2024)
- Year: 2024
- Articles: 9
- URL: https://medjrf.com/0929-8673/issue/view/10095
Anti-Infectives and Infectious Diseases
Meet the Regional Editor



Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer
Abstract
Cholangiocarcinoma is a rare type of cancer. Futibatinib is an irreversible, potent, selective inhibitor of fibroblast growth factor receptors (FGFR 1-4). On September 30, 2022, the US FDA first approved futibatinib to treat adult patients with bile duct cancer whose disease is unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene mutations or other classes of rearrangements. The approval of this medicine was based on phase 3 clinical trial results including an overall response rate (ORR) of 42% and a duration of response (DoR) of 9.7 months. This short perspective summarizes Futibatinibs synthesis, physicochemical properties, dosage, route of administration, mechanism of action, binding mode, pharmacodynamics, pharmacokinetics, drug interactions, adverse events, and possible mechanism of resistance.



Purine Nucleosides and Analogues Bearing Chiral Substituents: Medicinal Chemistry and Therapeutic Perspective
Abstract
Adenosine and its analogues play an important role as bioregulators of metabolic processes in animal cells, affecting a variety of metabolic functions by acting through the purinergic signaling system. Synthesis and structure-activity relationship for some known purine nucleosides bearing chiral substituents are considered in this work. These compounds represent a promising potential as drug prototypes for targeted therapy of cancer, metabolic dysfunctions, and neuronal disorders due to their enhanced selectivity to receptors of the purinergic signaling system. Derivatives of adenosine and guanosine containing a chiral substituent also manifest antiviral activity.



Mitapivat: A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency
Abstract
Mitapivat is an orally bioavailable small molecule allosteric activator of pyruvate kinase. It was approved by the US FDA on February 17, 2022, and the European Union in November 2022 for the treatment of hemolytic anemia in adult patients with pyruvate kinase deficiency. In this short perspective, physicochemical properties, synthesis, dosage and administration, mechanism of action, pharmacodynamics, pharmacokinetics, drug interactions, and adverse reactions of mitapivat are described.



LncRNA PVT1 as a Novel Biomarker for Diabetes-related Complications
Abstract
Diabetes is now afflicting an expanding population, and it has become a major source of concern for human health. Diabetes affects several organs and causes chronic damage and dysfunction. It is one of the three major diseases that are harmful to human health. Plasmacytoma variant translocation 1 is a member of long non-coding RNA. PVT1 expression profile abnormalities have been reported in diabetes mellitus and its consequences in recent years, suggesting that it may contribute to the disease's progression. Relevant literature from the authoritative database "PubMed" are retrieved and summarized in detail. Mounting evidence reveals that PVT1 has multiple functions. Through sponge miRNA, it can participate in a wide variety of signal pathways and regulate the expression of a target gene. More importantly, PVT1 is crucially implicated in the regulation of apoptosis, inflammation, and so on in different types of diabetes-related complications. PVT1 regulates the occurrence and progression of diabetes-related diseases. Collectively, PVT1 has the potential to be a useful diagnostic and therapeutic target for diabetes and its consequences.



Aging and Diabetic Kidney Disease: Emerging Pathogenetic Mechanisms and Clinical Implications
Abstract
Diabetic kidney disease (DKD) is one of the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide. With the overpowering trend of aging, the prevalence of DKD in the elderly is progressively increasing. Genetic factors, abnormal glucose metabolism, inflammation, mitochondrial dysregulation, and oxidative stress all contribute to the development of DKD. Conceivably, during aging, these pathobiological processes are likely to be intensified, and this would further exacerbate the deterioration of renal functions in elderly patients, ultimately leading to ESRD. Currently, the pathogenesis of DKD in the elderly is not very well-understood. This study describes an appraisal of the relationship between diabetic nephropathy and aging while discussing the structural and functional changes in the aged kidney, the impact of related mechanisms on the outcome of DKD, and the latest advances in targeted therapies.



Administration of Inhibitory Molecules through Nanoparticles in Breast Cancer Therapy
Abstract
According to Global Cancer Statistics, breast cancer is the second leading cause of mortality in women. While there are several treatments for breast cancer, they are not always effective. In most cases, after initial treatment, patients may present a low response to therapy, more severe relapses, and even drug resistance. Hence, more effective and targeted therapies are needed. Recently, the use of nanoparticles has emerged as a promising alternative that will allow the controlled release of drugs in response to stimuli, precise delivery to the site of action, lower levels of toxicity, and fewer side effects. In this review, we provide an overview of the recent evidence proposing the delivery of inhibitory molecules encapsulated in nanoparticles as a new therapy for breast cancer that targets the signaling pathways governing the processes of tumor formation, maintenance, and expansion.



Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis
Abstract
Background:Previous studies have found a potential role for statins in liver cancer prevention.
Objective:This study aimed to explore the effect of different types of statins on the incidence of liver cancer.
Methods:Relevant articles were systematically retrieved from PubMed, EBSCO, Web of Science, and Cochrane Library databases from inception until July 2022 to explore the relationship between lipophilic statins or hydrophilic statins exposure and the incidence of liver cancer. The main outcome was the incidence of liver cancer.
Results:Eleven articles were included in this meta-analysis. The pooled results showed a reduced incidence of liver cancer in patients exposed to lipophilic statins (OR=0.54, p < 0.001) and hydrophilic statins (OR=0.56, p < 0.001) compared with the non-exposed cohort. Subgroup analysis showed that both exposures to lipophilic (Eastern countries: OR=0.51, p < 0.001; Western countries: OR=0.59, p < 0.001) and hydrophilic (Eastern countries: OR=0.51, p < 0.001; Western countries: OR=0.66, p=0.019) statins reduced the incidence of liver cancer in Eastern and Western countries, and the reduction was most significant in Eastern countries. Moreover, atorvastatin (OR=0.55, p < 0.001), simvastatin (OR=0.59, p < 0.001), lovastatin (OR=0.51, p < 0.001), pitavastatin (OR=0.36, p=0.008) and rosuvastatin (OR=0.60, p=0.027) could effectively reduce the incidence of liver cancer, unlike fluvastatin, cerivastatin and pravastatin.
Conclusion:Both lipophilic and hydrophilic statins contribute to the prevention of liver cancer. Moreover, the efficacy was influenced by the region and the specific type of statins used.



Circulating Levels of 5-HT and BDNF in Adults with Autism Spectrum Conditions: An Investigation in a Sample of Subjects with Autism Spectrum Disorder, their First-degree Relatives and Controls
Abstract
Background:Several studies investigated circulating levels of serotonin (5- HT) and brain-derived neurotrophic factor (BDNF) in children with Autism spectrum disorder (ASD). More limited literature focused on ASD adults or on populations with subthreshold autism spectrum manifestations, such as relatives of ASD probands. This study aimed to investigate 5-HT and BDNF levels in adults with autism spectrum conditions. Correlations between levels of biochemical variables and ASD symptoms were also evaluated.
Methods:a sample of ASD adults, their first-degree relatives (Broad autism phenotype, BAP group), and controls were recruited and assessed with psychometric scales. Blood samples were collected from all participants. 5-HT and BDNF levels were measured by means of ELISA kits.
Results:ASD adults showed significantly lower platelet-poor plasma (PPP) 5-HT levels than BAP and control groups. No significant difference was found among groups for PPP BDNF levels and intra-platelet 5-HT levels. 5-HT levels were reported to be specifically correlated with some autism symptoms.
Conclusion:This work highlighted the presence in ASD adults of reduced PPP 5-HT levels than in other groups, without significant differences with respect to BDNF levels, supporting the hypothesis that biochemical correlates of ASD in adults may be different from those typically reported in children.


